Why CellCept

CellCept is a proven therapy, with over 22 years of transplant support across approved indications 1,2*

Since its launch in 1995, CellCept® (mycophenolate mofetil) has been helping transplant patients. CellCept is:

  • Indicated for kidney, heart, or liver transplant in adult patients to prevent organ rejection
  • Indicated for kidney transplants in children to prevent organ rejection
  • Available in a variety of formulations for adult and pediatric patients
    • Capsule, tablet, oral suspension, and intravenous formulations
    • Oral suspension for use in pediatric kidney transplant patients

To preserve your branded choice, indicate DAW (“dispense as written”) on each prescription for brand-name CellCept.

Review your state DAW laws

Please see below for Important Safety Information.

*CellCept is used in combination with cyclosporine and corticosteroids.

Help your patients access brand-name medicine

Your commercially insured patients can pay $15 per monthly co-pay with the CellCept® $15 Co-pay Card Program.

Sign up for CellCept updates

Get updates about CellCept, including patient assistance programs.